Altimmune, Inc. (ALT) stock
ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.53−0.03 (-1.92%)
Close on Nov 17, 2026Market cap $297.61MP/E –Yield –
Altimmune total assets
Total assets on the balance sheet at the end of each period.
Altimmune's total assets was $527.21M at Jun 30, 2026. For fiscal 2025 it was $279.93M, up 100.9% from the year before. Over ten years it grew 30.3% a year on average. The highest annual figure on record is $279.93M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $279.93M | +100.9% |
| FY2024 | Dec 31, 2024 | $139.31M | -33.9% |
| FY2023 | Dec 31, 2023 | $210.64M | +1.8% |
| FY2022 | Dec 31, 2022 | $206.93M | -5.5% |
| FY2021 | Dec 31, 2021 | $218.87M | -10.7% |
| FY2020 | Dec 31, 2020 | $245.12M | +353.4% |
| FY2019 | Dec 31, 2019 | $54.06M | -1.3% |
| FY2018 | Dec 31, 2018 | $54.75M | -13.1% |
| FY2017 | Dec 31, 2017 | $63.03M | +64.1% |
| FY2016 | Dec 31, 2016 | $38.40M | +93.3% |
| FY2015 | Dec 31, 2015 | $19.86M | -9.6% |
| FY2014 | Dec 31, 2014 | $21.98M | +28.2% |
| FY2013 | Dec 31, 2013 | $17.14M | -24.6% |
| FY2012 | Dec 31, 2012 | $22.74M | -0.3% |
| FY2011 | Dec 31, 2011 | $22.80M | -16.2% |
| FY2010 | Dec 31, 2010 | $27.20M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $527.21M | +177.0% |
| Q1 FY2026 | Mar 31, 2026 | $335.63M | +113.4% |
| Q4 FY2025 | Dec 31, 2025 | $279.93M | +100.9% |
| Q3 FY2025 | Sep 30, 2025 | $218.45M | +47.7% |
| Q2 FY2025 | Jun 30, 2025 | $190.35M | +9.8% |
| Q1 FY2025 | Mar 31, 2025 | $157.26M | -16.5% |
| Q4 FY2024 | Dec 31, 2024 | $139.31M | -33.9% |
| Q3 FY2024 | Sep 30, 2024 | $147.86M | -11.2% |
| Q2 FY2024 | Jun 30, 2024 | $173.35M | -5.4% |
| Q1 FY2024 | Mar 31, 2024 | $188.36M | +0.7% |
| Q4 FY2023 | Dec 31, 2023 | $210.64M | +1.8% |
| Q3 FY2023 | Sep 30, 2023 | $166.57M | -26.1% |
| Q2 FY2023 | Jun 30, 2023 | $183.32M | -12.7% |
| Q1 FY2023 | Mar 31, 2023 | $187.08M | -9.0% |
| Q4 FY2022 | Dec 31, 2022 | $206.93M | -5.5% |
| Q3 FY2022 | Sep 30, 2022 | $225.28M | -4.9% |
| Q2 FY2022 | Jun 30, 2022 | $209.91M | -18.4% |
| Q1 FY2022 | Mar 31, 2022 | $205.66M | -22.2% |
| Q4 FY2021 | Dec 31, 2021 | $218.87M | -10.7% |
| Q3 FY2021 | Sep 30, 2021 | $236.91M | +1.7% |
| Q2 FY2021 | Jun 30, 2021 | $257.26M | +150.9% |
| Q1 FY2021 | Mar 31, 2021 | $264.25M | +387.2% |
| Q4 FY2020 | Dec 31, 2020 | $245.12M | +353.4% |
| Q3 FY2020 | Sep 30, 2020 | $233.00M | +313.2% |
| Q2 FY2020 | Jun 30, 2020 | $102.54M | +65.5% |
| Q1 FY2020 | Mar 31, 2020 | $54.23M | -17.0% |
| Q4 FY2019 | Dec 31, 2019 | $54.06M | -1.3% |
| Q3 FY2019 | Sep 30, 2019 | $56.39M | +6.7% |
| Q2 FY2019 | Jun 30, 2019 | $61.98M | +19.0% |
| Q1 FY2019 | Mar 31, 2019 | $65.37M | +7.4% |
| Q4 FY2018 | Dec 31, 2018 | $54.75M | -13.1% |
| Q3 FY2018 | Sep 30, 2018 | $52.86M | -28.9% |
| Q2 FY2018 | Jun 30, 2018 | $52.10M | -42.6% |
| Q1 FY2018 | Mar 31, 2018 | $60.87M | +193.6% |
| Q4 FY2017 | Dec 31, 2017 | $63.03M | +64.1% |
| Q3 FY2017 | Sep 30, 2017 | $74.35M | -47.1% |
| Q2 FY2017 | Jun 30, 2017 | $90.84M | – |
| Q1 FY2017 | Mar 31, 2017 | $20.73M | – |
| Q4 FY2016 | Dec 31, 2016 | $38.40M | – |
| Q3 FY2016 | Sep 30, 2016 | $140.54M | – |
See a number that looks wrong?